252 related articles for article (PubMed ID: 23426935)
1. Gene amplification of EGFR, HER2, FGFR2 and MET in esophageal squamous cell carcinoma.
Kato H; Arao T; Matsumoto K; Fujita Y; Kimura H; Hayashi H; Nishiki K; Iwama M; Shiraishi O; Yasuda A; Shinkai M; Imano M; Imamoto H; Yasuda T; Okuno K; Shiozaki H; Nishio K
Int J Oncol; 2013 Apr; 42(4):1151-8. PubMed ID: 23426935
[TBL] [Abstract][Full Text] [Related]
2. Increased MET gene copy number negatively affects the survival of esophageal squamous cell carcinoma patients.
Wang Y; Jiang Z; Xu C; Wang H; Tan L; Su J; Wang X; Jiang D; Hou Y; Song Q
BMC Cancer; 2019 Mar; 19(1):240. PubMed ID: 30885149
[TBL] [Abstract][Full Text] [Related]
3. Alterations in epidermal growth factor receptors 1 and 2 in esophageal squamous cell carcinomas.
Gonzaga IM; Soares-Lima SC; de Santos PT; Blanco TC; de Reis BS; Quintella DC; de Oliveira IM; de Faria PA; Kruel CD; Andreollo NA; de Simão TA; Pinto LF
BMC Cancer; 2012 Dec; 12():569. PubMed ID: 23207070
[TBL] [Abstract][Full Text] [Related]
4. Identification of EGFR and KRAS mutations in Chinese patients with esophageal squamous cell carcinoma.
Liu QW; Fu JH; Luo KJ; Yang HX; Wang JY; Hu Y; Yang H; Bella E
Dis Esophagus; 2011 Jul; 24(5):374-80. PubMed ID: 21615826
[TBL] [Abstract][Full Text] [Related]
5. Expression profiles of HER2, EGFR, MET and FGFR2 in a large cohort of patients with gastric adenocarcinoma.
Nagatsuma AK; Aizawa M; Kuwata T; Doi T; Ohtsu A; Fujii H; Ochiai A
Gastric Cancer; 2015 Apr; 18(2):227-38. PubMed ID: 24626858
[TBL] [Abstract][Full Text] [Related]
6. Prognostic implications of
Kwon D; Yun JY; Keam B; Kim YT; Jeon YK
World J Gastroenterol; 2016 Nov; 22(44):9803-9812. PubMed ID: 27956804
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of gene amplification and protein expression of HER-2/neu in esophageal squamous cell carcinoma using Fluorescence in situ Hybridization (FISH) and immunohistochemistry.
Sato-Kuwabara Y; Neves JI; Fregnani JH; Sallum RA; Soares FA
BMC Cancer; 2009 Jan; 9():6. PubMed ID: 19128465
[TBL] [Abstract][Full Text] [Related]
8. Lapatinib inhibits the growth of esophageal squamous cell carcinoma and synergistically interacts with 5-fluorouracil in patient-derived xenograft models.
Hou W; Qin X; Zhu X; Fei M; Liu P; Liu L; Moon H; Zhang P; Greshock J; Bachman KE; Ye BC; Wang H; Zang CY
Oncol Rep; 2013 Aug; 30(2):707-14. PubMed ID: 23708506
[TBL] [Abstract][Full Text] [Related]
9. Increased gene copy number of HER2 and concordant protein overexpression found in a subset of eyelid sebaceous gland carcinoma indicate HER2 as a potential therapeutic target.
Lee MJ; Kim N; Choung HK; Choe JY; Khwarg SI; Kim JE
J Cancer Res Clin Oncol; 2016 Jan; 142(1):125-33. PubMed ID: 26141290
[TBL] [Abstract][Full Text] [Related]
10. MET amplification identifies a small and aggressive subgroup of esophagogastric adenocarcinoma with evidence of responsiveness to crizotinib.
Lennerz JK; Kwak EL; Ackerman A; Michael M; Fox SB; Bergethon K; Lauwers GY; Christensen JG; Wilner KD; Haber DA; Salgia R; Bang YJ; Clark JW; Solomon BJ; Iafrate AJ
J Clin Oncol; 2011 Dec; 29(36):4803-10. PubMed ID: 22042947
[TBL] [Abstract][Full Text] [Related]
11. HER2, MET and FGFR2 oncogenic driver alterations define distinct molecular segments for targeted therapies in gastric carcinoma.
Liu YJ; Shen D; Yin X; Gavine P; Zhang T; Su X; Zhan P; Xu Y; Lv J; Qian J; Liu C; Sun Y; Qian Z; Zhang J; Gu Y; Ni X
Br J Cancer; 2014 Mar; 110(5):1169-78. PubMed ID: 24518603
[TBL] [Abstract][Full Text] [Related]
12. Comparative analysis of the EGFR, HER2, c-MYC, and MET variations in colorectal cancer determined by three different measures: gene copy number gain, amplification status and the 2013 ASCO/CAP guideline criterion for HER2 testing of breast cancer.
Kwak Y; Yun S; Nam SK; Seo AN; Lee KS; Shin E; Oh HK; Kim DW; Kang SB; Kim WH; Lee HS
J Transl Med; 2017 Aug; 15(1):167. PubMed ID: 28764718
[TBL] [Abstract][Full Text] [Related]
13. Predictive value of EGFR overexpression and gene amplification on icotinib efficacy in patients with advanced esophageal squamous cell carcinoma.
Wang X; Niu H; Fan Q; Lu P; Ma C; Liu W; Liu Y; Li W; Hu S; Ling Y; Guo L; Ying J; Huang J
Oncotarget; 2016 Apr; 7(17):24744-51. PubMed ID: 27013591
[TBL] [Abstract][Full Text] [Related]
14. Resistance to cetuximab in EGFR-overexpressing esophageal squamous cell carcinoma xenografts due to FGFR2 amplification and overexpression.
Zhang Y; Pan T; Zhong X; Cheng C
J Pharmacol Sci; 2014; 126(1):77-83. PubMed ID: 25242085
[TBL] [Abstract][Full Text] [Related]
15. Genomic profiling of esophageal squamous cell carcinoma (ESCC)-Basis for precision medicine.
Yang JW; Choi YL
Pathol Res Pract; 2017 Jul; 213(7):836-841. PubMed ID: 28554745
[TBL] [Abstract][Full Text] [Related]
16. Correlation of epidermal growth factor receptor overexpression with increased epidermal growth factor receptor gene copy number in esophageal squamous cell carcinomas.
Yang YL; Xu KL; Zhou Y; Gao X; Chen LR
Chin Med J (Engl); 2012 Feb; 125(3):450-4. PubMed ID: 22490401
[TBL] [Abstract][Full Text] [Related]
17. Establishment and characterization of esophageal squamous cell carcinoma patient-derived xenograft mouse models for preclinical drug discovery.
Zhang J; Jiang D; Li X; Lv J; Xie L; Zheng L; Gavine PR; Hu Q; Shi Y; Tan L; Ge D; Xu S; Li L; Zhu L; Hou Y; Wang Q
Lab Invest; 2014 Aug; 94(8):917-26. PubMed ID: 24999713
[TBL] [Abstract][Full Text] [Related]
18. The relationship between the expression of VEGF, EGFR, and HER-2 mRNA in esophageal squamous cell carcinoma (ESCC) and clinicopathological features of different ethnic groups in Xinjiang.
Zhang L; Wang Y; Bai G; Zhang J; Yang M; Ma X
Tumour Biol; 2015 Dec; 36(12):9277-83. PubMed ID: 26099724
[TBL] [Abstract][Full Text] [Related]
19. Whole-Genome Sequencing Reveals Diverse Models of Structural Variations in Esophageal Squamous Cell Carcinoma.
Cheng C; Zhou Y; Li H; Xiong T; Li S; Bi Y; Kong P; Wang F; Cui H; Li Y; Fang X; Yan T; Li Y; Wang J; Yang B; Zhang L; Jia Z; Song B; Hu X; Yang J; Qiu H; Zhang G; Liu J; Xu E; Shi R; Zhang Y; Liu H; He C; Zhao Z; Qian Y; Rong R; Han Z; Zhang Y; Luo W; Wang J; Peng S; Yang X; Li X; Li L; Fang H; Liu X; Ma L; Chen Y; Guo S; Chen X; Xi Y; Li G; Liang J; Yang X; Guo J; Jia J; Li Q; Cheng X; Zhan Q; Cui Y
Am J Hum Genet; 2016 Feb; 98(2):256-74. PubMed ID: 26833333
[TBL] [Abstract][Full Text] [Related]
20. Clinicopathologic and molecular features of epidermal growth factor receptor T790M mutation and c-MET amplification in tyrosine kinase inhibitor-resistant Chinese non-small cell lung cancer.
Chen HJ; Mok TS; Chen ZH; Guo AL; Zhang XC; Su J; Wu YL
Pathol Oncol Res; 2009 Dec; 15(4):651-8. PubMed ID: 19381876
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
